熱門資訊> 正文
肿瘤研究所重申2025年指导，预测2026年收入
2026-01-12 21:36
- The Oncology Institute (TOI) on Monday reaffirmed its 2025 financial guidance and provided its preliminary 2026 outlook, expecting total revenue of $630 million to $650 million, up about 28% from the midpoint of 2025 guidance.
- The company said the increase reflects expansion of delegated contracts in Florida, higher volumes in its Dispensary segment, and new contract wins.
- Adjusted EBITDA for 2026 is projected between $0 million and $9 million, representing its first full year of adjusted EBITDA profitability as a public company at the midpoint.
- TOI also provided a longer-term view, projecting roughly 20% annual revenue growth through 2028, with potential margin expansion as the company continues to scale its asset-light capitated model and leverage SG&A.
- TOI -0.0% premarket to $4.18.
- Source: Press Release
More on The Oncology Institute
- The Oncology Institute: Making Progress
- The Oncology Institute, Inc. (TOI) Q3 2025 Earnings Call Transcript
- The Oncology Institute GAAP EPS of -$0.14 misses by $0.03, revenue of $136.6M beats by $13.97M
- TOI raises 2025 revenue outlook to $495M-$505M as pharmacy growth accelerates and adjusted EBITDA turns positive
- Seeking Alpha’s Quant Rating on The Oncology Institute
推薦文章
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
一周IPO | 賺錢效應持續火熱！年內24只上市新股「0」破發；「圖模融合第一股」海致科技首日飆漲逾242%
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
